Curious?

We can send you Clearmind news via email.

Thank You

Your contact information has been received. We will send you additional information via email shortly.
Oops! Something went wrong while submitting the form.

Clearmind Medicine invited to brief FDA at historic psychedelic hearing in Washington, DC   View press release.

Next-Generation Psychedelics Transformative Neuroplastogens

Clearmind Medicine is advancing the discovery and development of non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders, including Alcohol Use Disorder.

Next-Generation Psychedelic Medicine

Clearmind is working to develop a novel inexpensive, scalable, at-home, neuroplastogen-derived non-hallucinogenic treatment model for Alcohol Use Disorder without requiring costly supervised dosing.

Our First Indication

Alcohol Use Disorder

Alcohol Use Disorder (AUD)
the inability to reduce alcohol consumption, remains one of the most significant public health and addiction challenges in America today.

The FDA has not approved a new medication for AUD in 20 years

AUD is now recognized as a leading cause of preventable death among working-age Americans.
Some 10% of the US population meets the diagnostic criteria for AUD.
About 1 in 8 of all deaths among U.S. adults aged 20 to 64, and 1 in 5 of deaths among those aged 20 to 49 are attributed to alcohol abuse by the CDC.
Only 1 in 10 Americans suffering from AUD currently receives treatment.
[1] Annual Total Binge Drinks Consumed by U.S. Adults, 2015. Am J Prev Med. 2018 Apr;54(4):486-496
[2] Key Substance Use and Mental Health Indicators in the United States: Results from  the 2017 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, September 14, 2018
[3] Alcohol and Crime: An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime, U.S. Department of Justice, 1998
[4] Alcohol and Sexual Assault, National Institute on Alcohol Abuse and Alcoholism, 2001; 25(1): 43-51
[5] U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics, 2005

The Economic Cost

Alcohol and substance abuse have a higher economic burden than heart disease, depression and other leading health problems.

$193 billion3

Substance Abuse

$249 billion2

Alcohol Abuse

[1] US DOJ 2011, Bouchery, Horwood, Sacks, Simon & Brewer, 2011; Mrazek, Hornberger, Altar, & Degliar, 2014.

[2] Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer,R. D. (2015). 2010 national and state costs of excessive alcohol  consumption. American Journal of Preventive Medicine, 49(5), e73-e79.
[3] National Drug Intelligence Center. (2011). National drug threat assessment.  Washington, DC: U.S. Department of Justice.

The Competition

Large Market & Competitive Density

Our Solution

MEAI: A Novel Psychedelic
Non-Hallucinogenic Neuroplastogen

5-MeO-AI (5-Methoxy-2-aminoindane) also known as "MEAI"

Yale School of Medicine and Johns Hopkins University School of Medicine are home to Clearmind’s FDA-regulated Phase I/IIa clinical trials of CMND-100, its proprietary lead investigational candidate for alcohol use disorder, marking a pioneering milestone in the development of psychedelic-derived, non-hallucinogenic neuroplastogens.

How MEAI Works

Mark Haden, Clearmind’s VP Business Development, describes the MEAI treatment experience.

View Full Interview

It’s the ‘enough’ switch. [MEAI] signals to the brain that it is satisfied, that it wants nothing.

—Ezekiel Golan, Special Advisor for Innovation and New Initiatives

Why MEAI is Different

A New and Unique Psychedelic Treatment

The information presented in this table is based solely on the Company’s own market research. Actual information may contradict the Company’s findings.
[1] https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/
[2] Carnicella S, He DY, Yowell QV, Glick SD, Ron D. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol. 2010 Oct;15(4):424-33. doi: 10.1111/j.1369-1600.2010.00251.x. PMID: 21040239; PMCID: PMC3783954.

Our Patents

A Portfolio of 19 Patent Families

Clearmind patents consist of 19 utility patent families owned by the company.
These include 32 granted patents.

Our Treatments

Proprietary Treatment Candidates

Our Team

CEO Dr. Adi Zuloff-Shani is a recognized thought leader at the intersection of medicine, biotechnology, and capital markets, with extensive expertise in navigating the clinical trial process.

Adi Zuloff-Shani, PhD

Dr. Adi Zuloff-Shani is a distinguished biomedical R&D executive, scientist, and immunologist with more than two decades of strategic and operational leadership in healthcare. She brings deep commercial and technical expertise in navigating complex global regulatory pathways and highly regulated environments.

View Team

News Releases

17

September

2026

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Read More
11

September

2026

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Read More
8

September

2026

Clearmind Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following...
Read More
View All

Join Us

Let's Make History

Information

Reason for Inquiry

Thank you for sending your contact information—your details have been received.

Oops! Something went wrong. Please try again.
CMND Price Today by TradingView